<DOC>
	<DOCNO>NCT00659607</DOCNO>
	<brief_summary>This Post Marketing Surveillance ( PMS ) study aim review following investigate actual practice MicardisPlus Tablet market : 1 . Unexpected adverse drug reaction ( especially , serious adverse event ( SAEs ) ) 2 . Frequency incidence change adverse event ( AEs ) 3 . Factors safety profile study drug 4 . Factors efficacy profile study drug</brief_summary>
	<brief_title>Telmisartan+HCTZ ( Hydrochlorothiazide ) , Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>patient diagnose essential hypertension patient take Micardis Plus participate PMS study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>